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Abstract
This article describes the development of two simple and selective spectrophotometric methods for the determination of lan-
soprazole (LAN), an irreversible proton pump inhibitor, in both pure drug and capsule formulations. The methods are based on
the formation of charge-transfer (CT) complexes between LAN an electron donor and either picric acid or iodine as an electron
acceptor. The intensely coloured products formed were quantified based on the absorption bands at 410 nm for picric acid (method
A) and 360 nm for iodine (method B). The accuracy and precision of the methods were evaluated on intra-day and inter-day bases.
Beer’s law is obeyed in the concentration ranges of 2–32 and 0.8–12.0 g/ml LAN for method A and method B, respectively.
The molar absorptivity values, limits of detection (LOD) and limits of quantification (LOQ) have also been reported. The reaction
stoichiometry for both methods was evaluated by Job’s method of continuous variation and was found to be 1:1 (LAN: picric acid
and LAN: iodine). The proposed methods were successfully applied to the determination of LAN in capsules with good accuracy
and precision and without a detectable interference from common excipients. A statistical comparison of the methods revealed that
there is no significant difference between the official method and the proposed methods.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
Lansoprazole (LAN), which is chemically known
as 2-[[[3-methyl-4-(2,2,2 trifluoroethoxy) pyridine-2-
yl]methyl]sulfinyl]-1H-benzimidazole, is widely used as
an anti-ulcer drug (proton pump inhibitor) through inhi-
bition of H+, K+-ATP-ase in gastric parietal cells [1].behalf of Taibah University. This is an open access article under the
The drug assay is listed in the monograph of the United
States Pharmacopoeia (USP) [2] and the British Pharma-
copoeia (BP) [3]. The USP describes a high-performance
liquid chromatographic method and the BP recommends
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 potentiometric titration of LAN with NaOH in a 4:1
thanol:water mixture.
Several methods have been reported for the deter-
ination of LAN in pharmaceutical formulations,
ncluding high-performance liquid chromatography
HPLC) [4–17], ultra-performance liquid chromatog-
aphy (UPLC) [18–21], high-performance thin-layer
hromatography (HPTLC) [22,23], liquid chromatog-
aphy/tandem mass spectrometry (LC–MS) [24], cap-
llary electrophoresis [25,26], polarography [27–29],
oltammetry [30], UV spectrophotometry [31–38],
ow-injection analysis (FIA) [12,39], kinetic spec-
rophotometry [40,41], spectrofluorimetry [42,43] and
uorimetry [33]. Although those methods are sensi-
ive, some of them are time-consuming, complicated,
nd require expensive instrumentation. In particular,
hromatographic methods necessitate judicious con-
rol of the pH of the medium. Therefore, visible
pectrophotometry remains the technique of choice
ecause it is sensitive, economical, rapid and easily
anageable.
A number of colour formation reactions utiliz-
ng different reagents have been employed for the
isible spectrophotometric determination of LAN in
harmaceuticals [4,12,40,44–56]. The reported meth-
ds are based on complexation and oxidative coupling
44], formation of a charge-transfer complex [4,45],
edox followed by complexation or colour bleaching
46–49], bromination [50], ion-pair complexation reac-
ion [51–55] and coupling with diazotized p-nitroaniline
56]. However, most of the reported visible spectro-
hotometric methods suffer from one or more disadvan-
ages, such as poor sensitivity [4,44,45], a narrow range
f determination [47–50], use of a heating step [44,48],
nd use of an extraction step [52–55], as shown in
able 1.
The present work describes two rapid and simple vis-
ble spectrophotometric methods for the determination
f LAN by exploiting its basic nature and electron-
onating property. This determination is based on a
harge-transfer complexation of LAN with either picric
cid as a -acceptor or iodine as a -acceptor. Iodine has
een used for the spectrophotometric determination of
AN based on a charge-transfer complexation reaction
n a chloroform medium [45]. In the present study, the
ame reaction in a dichloromethane medium was found
o be very rapid and far more sensitive with a wide linear
ynamic range. The proposed methods utilizing picric
cid and iodine as reagents in dichloromethane were suc-
essfully applied to the determination of LAN, in either
ts pure form or in capsules, with good accuracy and
recision.University for Science 10 (2016) 80–91 81
2.  Experimental
2.1.  Instrument
A Systronics model 106 digital spectrophotometer
provided with 1-cm matched quartz cells was used for
all absorbance measurements.
2.2.  Materials
Pharmaceutical-grade LAN with a certified purity
of 99.80% was obtained from Cipla Ltd., Bangalore,
India. The following pharmaceutical preparations were
purchased from commercial sources and subjected to
analysis: Lan-15 (15 mg LAN per capsule) and Lan-30
(30 mg LAN per capsule) from Intas Pharmaceuticals,
Dehradun, India; Lanzol-15 and Lanzol-30 from Cipla
Ltd., Sikkim, India.
2.3.  Reagents  and  chemicals
All reagents and solvents used were of analytical-
reagent grade. Picric acid (0.4%, w/v) (S.D. Fine Chem.
Ltd., Mumbai, India) and iodine (0.1%, w/v) (Loba
Chemie, Mumbai, India) solutions were prepared in
dichloromethane (DCM) (Merck, Mumbai, India) and
kept in the dark when not in use.
2.4.  Stock  solution  of  LAN
Using a 100-ml calibrated flask, a 100-ml stock solu-
tion (100 g/ml LAN) was prepared by dissolving an
accurately weighed 10 mg aliquot of the pure drug in
DCM. This solution was further diluted with DCM to
obtain working concentrations of 40.0 and 20.0 g/ml
LAN for use as standards in methods A and B, respec-
tively.
2.5.  Sample  preparation
2.5.1.  Capsules
The contents of 20 capsules were combined, mixed,
weighed accurately and ground to a powder. A portion
of the powder equivalent to 5 mg of LAN was accu-
rately weighed and transferred into a 50-ml calibrated
flask. Then, 30 ml of DCM was added to the flask, and
the container was shaken thoroughly for 15–20 min to
extract the drug into the liquid phase. Finally, the solu-
tion was diluted to the mark with the same solvent, mixed
well and filtered using Whatman No. 42 filter paper.
An aliquot of the filtrate (100 g/ml LAN) was further
diluted with DCM to obtain working concentrations of
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Table 1
Comparison of the performance characteristic of the existing visible spectrophotometric methods with the proposed methods for the determination
of LAN in pharmaceuticals.
Sl. No. Reagent/s used λmax, nm Linear range (g/ml), ε
(L mol−1 cm−1)
Remarks Ref.
1 Chloranilic acid in acetonitrile 520 5–80
(ε = 3.45 × 103)
Less sensitive [4]
2 NBS-chloranilic acid using FIA
system
530 5–150 Less sensitive [12]
3 (a) KMnO4–NaOH
(b) KMnO4–NaOH kinetic
studies
610
530
5–150
5–70
Less sensitive, rate is critically
dependent on experimental
variables
[40]
4 (a) Acetyl chloride with CuSO4
(b) MBTH with ceric ammonium
sulphate
478.5
491.2
100–600
100–500
Less sensitive and requires
heating at 100 ◦C for 5 min
[44]
5 (a) DDQ in acetonitrile
(b) Iodine in chloroform
(c) Ternary complex formation
with Eosin and copper(II)
457
293 & 359
549
10–90 (ε = 4.10 × 103)
1.48–6.65
(ε = 2.72 × 104 & 5.65 × 104)
3.69–16.61 (ε = 1.58 × 104)
Requires heating at 60 ©C for
20 min for ternary complex
formation
[45]
6 Ceric ammonium sulphate and
iron(II) with (a)
orthophenanthroline; (b)
thiocyanate
510
470
2.5–30
(ε = 8.1 × 103)
2.5–25
(ε = 1.5 × 104)
Lengthy procedure and also
involve multiple-step reactions
[46]
7 Ceric ammonium sulphate with
(a) methyl orange and (b) indigo
carmine
520
610
0.5–7
(ε = 3.0 × 104)
0.25–3
(ε = 4.4 × 104)
Sensitive but involve
multiple-step reactions, narrow
linear range
[47]
8 Copper(II) sulphate with (a)
neocuproine and (b)
bathocuproine
460
480
0.2–3.6
(ε = 5.82 × 104)
0.2–3.2
(ε = 7.17 × 104)
Sensitive but requires heating on
a boiling water bath for 10 min
and narrow linear range
[48]
9 Iron(III) with ferricyanide 730 0.2–3.6
(ε = 6.78 × 104)
Sensitive but uses a slow reaction [49]
10 Bromate-bromide mixture and
iron(II) with (a) thiocyanate and
(b) orthophenanthroline
470
510
0.5–4
(ε = 3.97 × 104)
0.5–6
(ε = 3.07 × 104)
Involve multiple-step reactions [50]
11 (a) BCP in DCM
(b) BTB in DCM
400
430
0.5–15 (ε = 2.10 × 104)
1.25–20 (ε = 1.50 × 104)
– [51]
12 BCG 416 1–20 Extraction step is required [52]
13 (a) Supracen Violet 3B
(b) Tropaeolin OOO
(c) CAT- Gallocyanine
(d) NBS- Celestin Blue
590
500
540
540
5–40 (ε = 0.9232 × 104)
5–25 (ε = 1.0857 × 104)
2.5–12.5 (ε = 7.0997 × 104)
1–6 (ε = 2.3265 × 104)
Extraction step is required in a &
b, NBS solution unstable
[53]
14 (a) BTB
(b) BPB
(c) BCP
(d) BCG
419
417
416
414
2.5–25 (ε = 18,596)
4–30 (ε = 20,333)
4–40 (ε = 22,630)
4.5–45 (ε = 25,622)
Extraction step is required [54]
15 (a) Metanil yellow
(b) Methyl orange
440
450
20–70
6–16
Extraction step is required [55]
16 Diazotized p-nitroaniline in
alkaline medium-DMF
610 10–35 [56]
17 (a) Picric acid in DCM
(b) Iodine in DCM
410
360
2–32 (ε = 9.24 × 103)
0.8–12 (ε = 3.64 × 104)
Sensitive, no heating or extraction
step, no pH-adjustment, single
step reaction
Present
methods
ε, molar absorptivity; NBS, N-bromosuccinimide; FIA, flow injection analysis; DDQ, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone; MBTH, 3-
methyl-2-benzothiazolinone hydrazine; BCP, bromocresol purple; DCM, dichloromethane; BTB, bromothylmol blue; BCG, bromocresol green;
CAT, chloramine T; BPB, bromophenol blue; DMF, dimethylformamide.
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0 and 20 g/ml LAN for use in methods A and B,
espectively.
.5.2. Placebo
A placebo was composed of talc (20 mg), starch
15 mg), acacia (15 mg), methyl cellulose (20 mg),
odium citrate (15 mg), magnesium stearate (20 mg) and
odium alginate (15 mg); its solutions was prepared as
escribed under “capsules”.
.5.3.  Synthetic  mixture
To the placebo blank, 5 mg of LAN was added and
omogenized and then transferred to a 50-ml calibrated
ask. Solutions were prepared as described under “cap-
ules”.
.6.  Procedures
.6.1.  Method  A  (using  picric  acid)
Different aliquots (0.25, 0.5, 1.0, 2.0, 3.0 and 4.0 ml)
f a standard LAN (40 g/ml) solution in DCM were
ransferred to a series of 5-ml calibrated flasks using
 micro burette. To each flask, 1 ml of 0.4% picric
cid solution was added; the mixture was diluted to the
esired volume with DCM and mixed well. After 10 min,
he absorbance of each solution was measured at 410 nm
gainst a reagent blank.
.6.2.  Method  B  (using  iodine)
Varying aliquots (0.20, 0.5, 1.0, 2.0 and 3.0 ml) of a
tandard LAN (20 g/ml) solution were transferred into
 series of 5-ml calibrated flasks as described above.
o each flask was added 1 ml of 0.1% iodine solution,
nd the mixture was diluted to the desired volume with
CM and mixed well. The absorbance of each solution
as measured at 360 nm against a reagent blank.
In both methods, a standard calibration curve was pre-
ared by plotting the absorbance versus  concentrations
f LAN, and linear equations for the standard curves
ere calculated by linear regression.
.6.3. Procedure  for  stoichiometric  ratio
To establish the mole ratio between LAN and the
eagents used, Job’s method of continuous variations
f equimolar solutions was employed. The solutions
quivalent to 1.083 ×  10−4 and 5.414 ×  10−5 M LAN
ere prepared by dissolving the calculated amounts of
AN in DCM. Further, 1.083 × 10−4 M picric acid and
−5.414 ×  10 M iodine solutions were prepared in DCM.
 series of solutions was prepared in which the total vol-
me of LAN and reagent was maintained at 5 ml. The
rug and the reagent were mixed in various proportionsUniversity for Science 10 (2016) 80–91 83
(0:5, 1:4, 2:3, 3:2, 4:1 and 5:0), and the absorbance of
the resultant charge-transfer complex was measured at
410 nm in method A and at 360 nm in method B. The
absorbance was then plotted against the mole fraction of
the drug, [drug]/([drug] + [reagent]).
3.  Results  and  discussion
Mulliken’s theory of charge-transfer complexation
reactions has been extensively applied to the spectro-
photometric determination of several drugs containing
an electron-donating group [57–62]. The charge-transfer
complex forming reactions are based on the concept that
- and -acceptors react with basic nitrogenous com-
pounds (n-donor) to form charge-transfer complexes or
radical anions depending on the polarity of the solvent
used. LAN, being a basic nitrogen-containing com-
pound, was used with picric acid (as a -acceptor) and
iodine (as a -acceptor) in the proposed methods.
3.1.  Reaction  of  LAN  with  π-acceptor  (picric  acid)
The interaction of LAN with picric acid in a DCM
medium was found to yield an intense yellow-coloured
charge-transfer complex. The absorption spectra of the
coloured product and the reagent blank were recorded
between 380 and 500 nm and showed that both blank
and sample absorb maximally at 380 nm. However, the
maximum difference in absorbance between the sam-
ple and the blank was observed at 410 nm, as shown500480460440420400380
Wavel eng th, nm
Fig. 1. Absorption spectra for method A (16 g/ml LAN).
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blue shift of the free iodine band upon complexation
could be attributed to a perturbation of the iodine molec-
ular orbital (*) by a repulsive interaction between LAN
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 BlankFig. 2. Possible reaction pathway of a charg
charge-transfer complexation reaction based on the
transfer of a proton (H+ ion) from the hydroxyl group
of picric acid to the nitrogen atom in the benzimida-
zole ring of LAN. The fact that picric acid produces
a colourless solution in DCM, which becomes yellow
upon adding LAN, shows that picric acid is not dis-
sociated in the DCM solution. These observations also
indicate that picric acid functions as a proton donor in the
presence of LAN; the development of a yellow colour is
due to the formation of the picrate ion (phenolate ion)
[63]. The possible reaction pathway of LAN and picric
acid is shown in Fig. 2.
3.2.  Reaction  of  LAN  with  σ-acceptor  (iodine)
An increase in the absorbance of the violet colour of
iodine in DCM (a blank solution) was observed from
390 nm onwards (Fig. 3) due to the electronic transition
of free iodine [64,65]. The addition of LAN resulted in a
hypsochromic shift due to the charge transfer complex-
ation. Thus, the new band at 360 nm (Fig. 3) is assignedLAN:picric acid
fer complex between LAN and picric acid.
as a charge-transfer (CT) absorption band. The observed340 360 380 40 0 420 440 460 480
Wavelength, nm
Fig. 3. Absorption spectra for method B (4 g/ml LAN).
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ig. 4. Reaction pathway for the formation of a tri-iodide complex.
nd the iodine molecule in the CT complexes [58,66].
ormation of the tri-iodide complex as a result of the
nteraction between the n-donor (D) and the -acceptor
I2) has been reported [58,67]. The reaction pathway for
his reaction is shown in Fig. 4 and can be summarized
y the following steps: (a) formation of the associative
uter-sphere CT complex D−I+I−, (b) transformation to
he dissociative inner-sphere complex [D−I+]+I−, and
c) association with another iodine molecule to form the
ri-iodide complex I3−. The lone pair of electrons on
enzimidazole nitrogen atom in LAN emphasized this
nteraction pathway.
.3.  Optimization  of  reaction  conditions
.3.1.  Effect  of  solvent
To select a suitable solvent for CT complex forma-
ion, the reaction of LAN with picric acid and iodine
as monitored in different solvents, namely, DCM, 1,2-
ichloroethane (DCE), chloroform, benzene, acetonitrile
ACN), dioxane and methanol. In both methods, the sen-
itivity of the reaction was found to be very high in ACN;
owever, the reagent blank was unstable in this medium.
CM demonstrated superiority over other solvents in
erms of sensitivity, minimum blank absorbance and sta-
ility of both blank and sample (Fig. 5a and b). Hence,
CM was used as the reaction medium in addition to
eing the solvent for solutions of LAN and the reagents
picric acid and iodine).
.3.2.  Effect  of  reagent  concentration
The effect of reagent concentration on the absorption
ntensities for the selected wavelengths was ascertained
sing different volumes of reagents, picric acid (0.4%)
n method A and iodine (0.1%) in method B. In method
, the blank absorbance was found to increase with an
ncrease in concentration of picric acid, and 1.0 ml of
.4% picric acid was found to provide maximum sensi-
ivity with a minimum blank absorbance (Fig. 6). Hence,
 ml of 0.4% picric acid in a total volume of 5 ml was
sed throughout the experiment. In method B, both sen-
itivity and the blank absorbance were found to increase
ith increasing concentrations of the iodine, as shown in
ig. 6. Considering the minimum blank absorbance and
he sensitivity, 1 ml of 0.1% iodine was fixed in a total
olume of 5 ml for method B.Fig. 5. Effect of solvents on the colour development: (a) method A
(16 g/ml LAN); (b) method B (4 g/ml LAN).
3.3.3.  Effect  of  reaction  time  and  stability  of  the
reaction product
The optimum reaction time for the development of
colour at ambient temperature (25 ±  2 ◦C) was studied,
and it was determined that complete colour development
was achieved after 10 min for method A. In method B,
the reaction was found to be instantaneous. The formed
colour was stable for at least 2 h in method A and 30 min
in method B.
3.4.  Stoichiometry
The molar ratio of LAN to - or -acceptor (picric
acid or iodine, respectively) in the formed complexes was
determined by applying Job’s method of continuous vari-
ations. In both cases, the plot reached a maximum value
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method A; and 4 g/ml LAN and 0.1% iodine in method B).
at a mole fraction of 0.5, which indicated the formation
of a 1: 1 (LAN: picric acid or iodine) complex, as shown
in Fig. 7a and b. The conditional stability constants (Kf)
of the charge-transfer complexes were calculated using
the data from the continuous variations method in the
following equation [68]:
Kf = A/Am(1 −  A/Am)n+2CM(n)n
where A  and Am are the observed maximum absorbance
and the absorbance value when all of the drug present
is associated, respectively; CM is the molar concentra-
tion of the drug at maximum absorbance; and n is the
stoichiometry. This resulted in Kf values of 3.19 ×  107
and 1.46 ×  107 for LAN-picric acid and LAN-iodine
complexes, respectively.
4.  Method  validation
4.1.  Analytical  data
Under optimum experimental conditions, the
absorbance responses were linear in relation to the
concentration of LAN over the ranges of 2–32 g/ml in
method A and 0.8–12.0 g/ml in method B. The calibra-
tion graph in each instance is described by the equation:
Y  =  a  +  bX
where Y  = absorbance, a  = intercept, b  = slope and
X = concentration in g/ml; the fit was obtained by
the method of least squares. The molar absorptivity,
Sandell’s sensitivity, correlation coefficient, limit of
detection (LOD), limit of quantification (LOQ), standardFig. 7. Job’s continuous – variations plots: (a) for method A and (b)
for method B.
deviation of intercept (Sa) and standard deviation of
slope (Sb) for both methods are calculated as per the cur-
rent ICH guidelines [69] and are summarized in Table 2.
4.2.  Accuracy  and  precision
To evaluate the accuracy and precision of the pro-
posed methods, solutions containing three different
concentrations of LAN were prepared and analyzed in
seven replicates during the same day (intra-day) and
over five consecutive days (inter-day), and the results
are summarized in Table 3. The low values of the rela-
tive standard deviation (RSD ≤  1.97% for intra-day) and
(RSD ≤  2.71% for inter-day) indicate the high precision
S.A.M. Abdulrahman et al. / Journal of Taibah 
Table 2
Sensitivity and regression parameters.
Parameter Method A Method B
λmax, nm 410 360
Linear range, g/ml 2–32 0.8–12.0
Molar absorptivity (ε),
L mol−1 cm−1
9.24 × 103 3.64 × 104
Sandell sensitivitya, g/cm2 0.04 0.01
Limit of detection (LOD), g/ml 0.62 0.08
Limit of quantification (LOQ),
g/ml
1.89 0.23
Regression equation, Yb
Intercept (a) 0.002 0.014
Slope (b) 0.026 0.09
Standard deviation of a (Sa) 0.015 0.126
Standard deviation of b (Sb) 0.0005 0.012
Regression coefficient (r) 0.999 0.999
a Limit of determination as the weight in g per ml of solution, which
corresponds to an absorbance of A = 0.001 measured in a cuvette of
c
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Mross-sectional area 1 cm2 and l = 1 cm.
b Y = a + bX, where Y is the absorbance, X is concentration in g/ml,
 is intercept, b is slope.
f the proposed methods. Additionally, the accuracy of
he proposed methods was evaluated in terms of relative
rror (% RE), and from the results shown in Table 3, it
s clear that the accuracy is good (RE ≤  2.81%).
.3.  Selectivity
The selectivity of the proposed methods was eval-
ated by analysis of a placebo blank solution, and the
esulting absorbance readings in both methods were the
ame as the reagent blank, indicating that no interfer-
nce from the placebo occurred. Non-interference from
he placebo was further confirmed by carrying out a
ecovery study from the synthetic mixture with percent
ecoveries of 103.8 ±  2.02 and 97.96 ±  1.96 for method and method B, respectively. These results confirm the
electivity of the proposed methods in the presence of
ommonly employed excipients.
able 3
valuation of intra-day and inter-day accuracy and precision.
ethod LAN taken, g/ml Intra-day accuracy 
LAN found, g/ml
ethod A (using picric acid) 16.0 16.35 
24.0 24.54 
32.0 32.58 
ethod B (using iodine) 4.0 3.94 
6.0 6.04 
8.0 8.10 
a RE: Relative error.
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4.4.  Robustness  and  ruggedness
Robustness and ruggedness were checked at three dif-
ferent drug levels. The method robustness was evaluated
by making small incremental changes in two experi-
mental variables, reagent volume and reaction time. The
effect of the changes in the absorbance reading of the
resulting complexes in both methods was found to be
negligible, thereby confirming the robustness of the pro-
posed methods. To check the ruggedness, analysis was
performed by four different analysts and on three differ-
ent spectrophotometers by the same analyst. The inter-
mediate precision, expressed as percent RSD, is a mea-
sure of robustness and ruggedness and was determined
to be within the acceptable limits, as shown in Table 4.
4.5.  Application  to  analysis  of  capsules
The proposed methods were successfully applied to
the determination of LAN in commercial capsules. The
results obtained by the proposed methods were com-
pared to those of the reference method [3] by applying
Student’s t-test for accuracy and the F-test for preci-
sion at the 95% confidence level. The reference method
involved the potentiometric titration in which LAN in
a 4:1 ethanol:water mixture was titrated against 0.1 M
NaOH. The results in Table 5 show that Student’s t- and
F-values at the 95% confidence level are less than the
theoretical values, which confirmed that there is good
agreement between the results obtained using the pro-
posed methods and those obtained using the reference
method with respect to accuracy and precision.
4.6.  Recovery  studiesThe accuracy and validity of the proposed methods
were further evaluated by performing recovery studies.
Pre-analyzed capsule powder was spiked with pure LAN
at three concentration levels (50%, 100% and 150%
and precision (n = 7) Inter-day accuracy and precision (n = 5)
 %REa %RSDb LAN found, g/ml %RE %RSD
2.19 1.97 16.45 2.81 2.15
2.25 1.85 24.65 2.71 2.69
1.81 1.79 32.79 2.47 2.21
1.50 1.19 4.10 2.50 1.63
0.67 1.24 6.10 1.67 1.49
1.25 1.11 7.85 1.88 1.73
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Table 4
Robustness and ruggedness expressed as intermediate precision (%RSD).
Method LAN taken, g/ml Method robustness Method ruggedness
Parameter altered Inter-analysts’
%RSD, (n = 4)
Inter-instruments’
%RSD, (n = 3)Volume of picric acid/iodinea
(n = 3)
Reaction timeb
(n = 3)
Method A (using picric acid) 16.0 2.17 1.75 1.42 2.26
24.0 1.93 1.82 1.27 2.41
32.0 2.05 1.79 1.21 2.31
Method B (using iodine) 4.0 1.33 – 0.87 2.19
6.0 1.27 – 1.05 2.28
8.0 1.21 – 0.94 2.17
a The volumes of picric acid in method A and the volumes of iodine in method B were 0.8, 1.0 and 1.2 ml.
b In method A, the reaction times were 9, 10 and 11 min.
Table 5
Results of analysis of capsules by the reference and proposed methods.
Capsule Brand name Label claim, mg/capsule Founda (Percent of label claim ± SD) (n = 5)
Reference method Method A (using picric acid) Method B (using iodine)
Lan-15 15 100.7 ± 0.84 101.3 ± 1.11
t = 0.97
F = 1.75
99.42 ± 0.92
t = 2.30
F = 1.20
Lanzol-15 15 100.5 ± 0.89 101.7 ± 1.04
t = 1.96
F = 1.37
98.97 ± 0.99
t = 2.57
F = 1.24
Lan-30 30 101.2 ± 0.97 102.5 ± 1.13
t = 1.96
F = 1.36
101.9 ± 1.08
t = 1.08
F = 1.24
Lanzol-30 30 99.87 ± 1.00 98.17 ± 1.07
t = 2.60
F = 1.14
99.23± 1.02
t = 1.00
F = 1.04
a Mean value of five determinations.
The value of t (tabulated) at 95% confidence level and for four degrees of freedom is 2.78.
The value of F (tabulated) at 95% confidence level and for four degrees of freedom is 6.39.
Table 6
Accuracy assessment by recovery experiment.
Method Capsule
studied
LAN in
capsule, g/ml
Pure LAN
added, g/ml
Total found,
g/ml
Pure LAN recovereda
Percent ± SD
Method A (using picric acid) Lan-15 8.10 4.0 12.22 103.0 ± 1.21
8.10 8.0 16.4 103.8 ± 1.42
8.10 12.0 19.96 98.83 ± 1.37
Method B (using iodine) Lan-15 3.98 2.0 6.05 103.5 ± 1.14
3.98 
3.98 
a Mean value of three measurements.
of that in capsule powder), and the total was deter-
mined using the proposed methods. In both cases, the
added LAN recovery percentage values ranged from
98.00 to 103.8% with a standard deviation of 1.08–1.42
(Table 6), indicating that the recovery was good and
that the co-formulated substance did not interfere in the
determination of concentration.4.0 7.90 98.00 ± 1.26
6.0 10.11 102.2 ± 1.08
5.  Conclusions
Two simple and rapid spectrophotometric methods
for the determination of LAN in capsules were devel-
oped and validated as per the ICH guidelines. These
methods are based on well-characterized charge-transfer
complexation reactions utilizing picric acid and iodine
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lthough iodine has been used previously for the deter-
ination of LAN in a chloroform medium [45], the
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ound to be superior to the reported method with respect
o sensitivity, rapidity and linear range. The previously
eported method determined LAN over a concentra-
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eaction time. The proposed LAN-iodine method deter-
ines LAN in concentrations from 0.8 to 12.0 g/ml
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